Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus Lomustine vs Lomustine in Recurrent Glioblastoma
NCT00948389Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2009
- Primary completion
- May 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of dasatinib in glioblastoma (GBM), sponsored by Bristol Myers Squibb. Started Oct 2009; status: terminated.
02
Drugs
dasatinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00948389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948389.